After the United Kingdom’s Ministry of Health (Minsa) authorized the laboratory of AstraZeneca, they will carry out the clinical trials of its candidate for a vaccine against COVID-19, the National Institute of Health (INS) published the data sheet in which it is specified that these will be done in the private sector.
The Polyclinic Specialized in Neurology SAC, to the unit of International Clinic Research and to Ricardo Palma Clinic Research Center (ICRC); such as the establishments where the tests will take place.
They also specified that they would need 5,000 volunteers between the ages of 18 and 64; however, they also indicated that the participation of older adults over 65 will be allowed. They also specified that the total duration of the trial will be 24 months.
Listed criteria that must be met to participate in the clinical trial
- History of allergy to any component of the vaccine
- History of Guillain-Barré syndrome or any other demyelinating condition
- Significant infection or other acute illness, including a fever> 100 ° F (> 37.8 ° C), on the day before or on the day of randomization
- History of laboratory-confirmed SARS-CoV-2 infection
- Any confirmed or suspected state of immunosuppression or immunodeficiency, including asplenia
- Recurrent severe infections and use of immunosuppressive medication within the last 6 months (≥ 20 mg per day of prednisone or its equivalent, administered daily or every other day for ≥ 15 days within the 30 days prior to administration of the study intervention), among others.
- The AstraZeneca vaccine candidate is being developed in conjunction with the University of Oxford, also in the UK. Regarding the tests of the American laboratory Johnson & Johnson, the INS has not yet released the data sheet of these tests.